Product description

The IVCC is looking to develop three new insecticidal active ingredients with different modes of action that show no cross resistance with any currently used insecticides for vector control. These new active ingredients will then be used to develop novel vector control products.

Required performance or efficacy

100% control and knockdown  on textile and wall surfaces against fully susceptible and known resistant Anopholes and Aedes mosquitoes at levels that will allow easy deployment for vector control.  The active ingredient must have a contact killing mechanism, not be impacted by known resistance mechanisms and contain no structurally alerting toxophores.

Stability

The active ingredient should be stable to UV to ensure deployment is practical for at least 1 year for LLIRS and at least 2 years for LLINs. It should demonstrate stability across a wide pH range to ensure stability when deployed in LLIRS on a wide range of surfaces

Cost of implementation in the field

It is a prerequisite of the global access plan that the product should be affordable and competitively priced for target populations in disease endemic countries. Cost efficacy should be equal or better than WHO approved insecticides.  The product will be benchmarked against the current costs for other AIs on the market.  This will be reviewed at key milestones.   

Safety and regulatory profile

The active ingredients used must meet WHOPES risk assessment standards.  An initial positive risk assessment for the active ingredients must be submitted with the proposal for review and comment by the IVCC ESAC toxicology, eco-toxicology and risk assessment professionals.

A full standard regulatory package will be developed for the active ingredient.  As part of this package, information on the efficacy, safety and acceptability of the product shall be submitted in accordance with WHO guidelines.  The dossier will be submitted to the appropriate regulatory authority, including WHOPES, for registration against internationally accepted criteria.

Suitability for end users

The active ingredients should have no features that cause end users to oppose their use, e.g. they should leave no visible residue, there should be no lasting adverse odour etc.

Manufacturing considerations

A conceivable manufacturing route needs to be available to produce the active ingredient.

IP issues

There should be freedom to operate from any existing patent. All background and foreground IP should be freely made available for the active ingredient’ss development and use in vector control in disease endemic countries.

 

Desirable Product Characteristics